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Abstract In cancer, Wnt/β-catenin signaling is ubiquitously
referred to as an “oncogenic” pathway that promotes tumor
progression. This review examines how the regulation and
downstream effects of Wnt/β-catenin signaling in cancer
varies depending on cellular context, with a focus on
malignant melanoma. We emphasize that the cellular homeo-
stasis of Wnt/β-catenin signaling may represent a more
appropriate concept than the simplified view of the Wnt/β-
catenin pathway as either oncogenic or tumor-suppressing.
Ultimately, a more refined understanding of the contextual
regulation of Wnt/β-catenin signaling will be essential for
addressing if and how therapeutic targeting of this pathway




At least two overlapping signaling pathways are regulated
by the family of secreted glycoproteins known as Wnts [1].
The highly conserved “canonical” Wnt/β-catenin signaling
pathway is activated by the binding of Wnt ligand to the
receptorsfrizzled(FZD)andlow-densitylipoproteinreceptor–
relatedprotein5/6(LRP5/6),triggeringaseriesofdownstream
events that culminate in the cytosolic accumulation and
nuclear translocation of the multifunctional protein β-
catenin. Interaction of β-catenin with transcription factors of
the TCF and LEF family results in the regulation of certain
target genes that mediate the ultimate effects of this pathway
on cellular processes including cell fate, proliferation, and
migration. There are also one or more “non-canonical” or β-
catenin–independentWnt signalingpathwaysthatare lesswell
understand, and that act in a β-catenin–independent manner
leading to changes to cytoskeletal dynamics, adhesion, and
motility [1]. Interestingly, β-catenin–independent Wnt sig-
naling can antagonize Wnt/β-catenin signaling in develop-
ment [2], regeneration [3], and cancer [4, 5], highlighting the
complex interplay between downstream effectors of Wnt
signaling.
Wnt pathways have been intimately linked to cancer
ever since the original realization that the mouse mammary
oncogene int-1 is a homologue of the Drosophila wingless
(Wg) gene [6], resulting in the portmanteau family
designation of “Wnt.” Subsequent studies have implicated
Wnt signaling in almost every major disease and cancer
model, reflecting the importance of major developmental
pathways in the pathogenesis of adult disease processes [7,
8]. Most dramatically, almost all colorectal carcinomas
harbor inactivating mutations in the gene for adenomatous
polyposis coli (APC), which forms a complex with AXIN
and glycogen synthase kinase 3-β (GSK3B) that normally
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DOI 10.1007/s11912-010-0114-3phosphorylates β-catenin to target the protein for
proteasomal degradation. Mutations or loss of APC in
colorectal carcinoma therefore prevent degradation of β-
catenin and consequently lead to constitutive activation
of the pathway. Further studies using both cell-based
models and transgenic animal models have validated the
essential role of Wnt dysregulation in the formation of
colorectal cancer, establishing this disease paradigm as a
primary model for studying the molecular mechanisms of
Wnt/β-catenin signaling in oncogenesis [9, 10].
Since the initial demonstration that Wnt signaling regulates
the stability and translocation of β-catenin [11], the immuno-
histochemical detection of nuclear β-catenin in both labora-
tory models and in patient tumors has been widely employed
as a surrogate for demonstrating activation of the Wnt/β-
catenin pathway [1]. In several cancer models including
colorectal carcinoma, breast cancer, and esophageal carcino-
ma, the presence of nuclear β-catenin in cancer tissue
compared to normal tissue has implicated this signaling
pathway in cancer biology. Further studies have observed
that the presence of nuclear β-catenin can predict decreased
survival in these cancers, solidifying the importance of this
pathway in oncogenesis and in cancer progression.
Not surprisingly, Wnt/β-catenin signaling has also been
implicated in a broad variety of noncancerous medical
conditions. Genetic polymorphisms in LRP5/6 that decrease
Wnt/β-catenin signaling have been linked to altered bone
density [12], metabolic syndrome [13], and to Alzheimer’s
disease [14]. In normal tissues and organs, without genetic
polymorphisms or mutations, Wnt/β-catenin signaling is
activated in every animal that displays regeneration, and β-
catenin signaling is also activated in traumatic brain injury,
which does not display extensive regeneration [15]. More-
over, it is clear that attenuating β-catenin signaling delays
regeneration while augmenting β-catenin signaling often
enhances the rate of regeneration, as determined by analysis
of tail fin regeneration in zebrafish, and liver regeneration in
both mouse and zebrafish [16]. Given that regeneration
employs progenitor cells it should come as no surprise that
Wnts regulate embryonic stem cells, though there is not a
consensus on the precise roles.
The increasing body of literature on Wnt/β-catenin
signaling in disease has generated tremendous interest in the
potential therapeutic targeting of this pathway. Until recently,
the only modulator of Wnt/β-catenin signaling approved by
the US Food and Drug Administration was lithium chloride,
which prevents the degradation of β-catenin by inhibiting its
phosphorylation by GSK3B. More recent studies have
identified small molecule activators as well as inhibitors of
Wnt/β-catenin signaling that may eventually have therapeutic
utility in patients [17, 18, 19￿￿, 20, 21, 22￿￿].
In parallel with studies on Wnt/β-catenin signaling in
cancer and other diseases, substantial progress has also
been made in understanding how this pathway regulates
developmental processes such as melanocyte differentia-
tion. Wnt/β-catenin signaling is a major regulator of the
pigmented cell lineage, playing a major role in determining
the fate of neural crest cells and its derivative pigment cell
lineages. Wnt/β-catenin signaling directly regulates the
expression of microphthalmia transcription factor (MITF), a
major determinant of both melanocyte development and
melanoma progression [23–25]. Wnt3a ligand is one of
only three factors required to differentiate a pluripotent
human embryonic stem cell into a functional melanocyte,
further highlighting the critical role of this pathway in
pigment cell biology [26]. Not surprisingly, the Wnt/β-
catenin pathway has been implicated in the pathogenesis of
both benign melanocytic nevi as well as in malignant
melanoma.
Not as Oncogenic as We Thought
In the last two decades since the initial identification of
activated Wnt/β-catenin signaling in the murine breast
cancer model, the role of this pathway in promoting
proliferation has fostered the prevailing view that Wnt/β-
catenin signaling is uniformly “oncogenic” [27]. Does the
existing literature support that Wnt/β-catenin signaling is
truly “oncogenic” in melanoma? The Wnt/β-catenin path-
way would not fit the original definition of an oncogene as a
gene or pathway that causes cancer when aberrantly activated,
since the forced expression of a melanocyte-specific, nonde-
gradable, constitutively active β-catenin mutant in either
transgenic or Cre/lox systems is not enough to induce
melanoma in mice [28]. As our understanding of cancer has
advanced, the term “oncogenic” has seemingly broadened to
include any gene or pathway implicated in cancer progres-
sion, a benchmark that is more difficult to define. The finding
that constitutive activation of Wnt/β-catenin signaling
increases the proliferation of murine melanoma cells in vitro,
accompanied by MITF-dependent increases in clonogenic
growth, implicates this pathway as a promoter of melanoma
progression [29]. Likewise, the activation of this pathway
acts in concert with activation of Ras to promote increased
tumor formation in transgenic mice, further suggesting a role
in tumor promotion [28]. In contrast to these studies in cell
culture and mouse-based models, there have been several
recent reports that activation of Wnt/β-catenin signaling in
patient tumors, as monitored by increased levels of nuclear
β-catenin, correlates with an improved rather than poorer
prognosis [5, 30–32]. Consistent with the data seen in human
patients, forced expression of Wnt3a in B16 melanoma cells
leads to decreased proliferation in vitro and in vivo, along
with the upregulation of genes associated with melanocyte
differentiation that are frequently lost with melanoma
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positive for nuclear β-catenin, and studies have observed a
loss of nuclear β-catenin with melanoma progression to
metastases [31]. Since the rate of transformation of nevi to
melanomas is estimated to be very low [33], these collective
observations from patients bring up the possibility that Wnt/
β-catenin signaling may not be oncogenic in any sense, but
ratherisrequiredtomaintainahomeostaticbalancethat,when
disrupted or lost, can lead to early melanoma transformation.
Another interesting aspect of Wnt/β-catenin signaling in
melanoma involves β-catenin–independent Wnt signaling
activated in many (but not all) contexts by WNT5A.
WNT5A was first linked to disease as a gene that was
more highly expressed in aggressive and late-stage mela-
nomas [34], and the immunohistochemical detection of
high WNT5A in tumors was subsequently correlated with
decreased patient survival [35]. Studies on WNT5A in
melanoma have focused largely on the effects of this ligand
on cell motility, based on the precedent that WNT5A
regulates the movement of cells during the convergent-
extension phase of vertebrate gastrulation [2, 36]. Interest-
ingly, at least two studies have shown that WNT5A inhibits
the transcription of Wnt/β-catenin target genes in melanoma,
recapitulating the ability of β-catenin–independent Wnt
signaling to inhibit Wnt/β-catenin signaling that was first
observed in developmental models [4, 5]. This finding
suggests that the acquisition of increased WNT5A with
later-stage tumors may be involved with the inhibition and/or
loss of Wnt/β-catenin signaling seen during melanoma
progression from benign nevi to metastases.
Ifone looks atthe available datafrompatient-basedstudies
of tumor tissue, the notion that Wnt/β-catenin signaling may
not be universally oncogenic is supported by studies in a
growing number of diseases. In the case of medulloblastoma,
all patients with extensive nuclear β-catenin staining had a
5-year overall survival rate of 92.3% versus a rate of 65.3% in
patients with nucleonegative tumors [37]. Furthermore, in a
study of 72 children, all six children who had an activating
mutation in the CTNNB1 gene were alive and free of disease
5 years following diagnosis, compared to a survival rate of
53.7% for the CTNNB1 wild-type group [38￿]. In addition,
these favorable activating mutations of β-catenin correlate
with a gene expression profile that distinguishes it from other
medulloblastoma subtypes [39]. More limited studies in
prostate cancer [40], ovarian cancer [41], and even in late-
stage colorectal carcinoma [42] also show that the presence
of active Wnt/β-catenin signaling is correlated with im-
proved patient outcomes.
Ultimately, debates on whether Wnt/β-catenin signal-
ing is oncogenic are less relevant than understanding
whether the therapeutic activation of this pathway could
be beneficial for various diseases, including melanoma
and other cancers. Interestingly, forced activation of Wnt/
β-catenin signaling in the setting of Kras-driven murine
pancreatic cancer models can antagonize the development
of pancreatic intraepithelial neoplasia lesions, and drive
the development of tumors that resemble more benign
human solid pseudopapillary neoplasms rather than more
malignant pancreatic ductal adenocarcinoma [43￿￿, 44].
This type of intriguing observation invites the hypothesis
that Wnt/β-catenin signaling can be leveraged clinically to
prevent aggressive tumors at the expense of potentially
acquiring tumors that are more benign and treatable.
Similarly, the improved survival seen with activating β-
catenin mutations in medulloblastoma, which is largely a
Hedgehog-driven tumor, may also reflect the ability of
Wnt/β-catenin signaling to promote cell fates that are less
aggressive, a hypothesis supported by observations with
genome-wide transcriptional profiling of patient tumors.
Although in theory the idea of activating Wnt/β-catenin
signaling in cancer patients could be achieved, further
studies will be needed to address the timing, strength, and
duration of Wnt/β-catenin signaling required for the
desired outcome.
In melanoma, activation of Wnt/β-catenin signaling
through the forced expression of Wnt3a or through treatment
of cells with soluble Wnt3a ligand results in the decreased
tumor cell proliferation in vitro and in vivo, as well as the
transcriptional upregulation of genes associated with melano-
cyte differentiation [5]. Some of these genes, such as Trpm1/
melastatin, are lost with melanoma progression. The ability
of Wnt/β-catenin signaling to drive the expression of certain
differentiation-related genes likely reflects its role as a major
regulator of melanocyte development. Further studies will
ultimately address whether the therapeutic activation of Wnt/
β-catenin signaling in human melanoma patients is either
practicable or beneficial.
Wnt and Cellular Homeostasis
Perhaps the time has come when we should not categorize
signaling pathways as either oncogenic or tumor-
suppressive, but instead view them in the context of cellular
homeostasis. Most definitions of cellular homeostasis
include the property of cells to maintain a viable and
healthy state through the constant adjustment of various
inputs such as biochemical pathways. In this context, it is
not hard to envision a role for Wnt/β-catenin signaling in
maintaining cell fate and regulating proliferation for both
cancerous and noncancerous cells. The transcriptional
response of Wnt/β-catenin signaling itself illustrates the
importance of ongoing homeostasis, since many of the
classical β-catenin–dependent target genes, including
DKK1, AXIN2, TCF7, and LEF1 , can function as feedback
inhibitors to modulate the pathway.
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catenin signaling maintains normal adult tissue, including in
intestinal crypts and in hair follicle units. Benign melanocytic
nevi are similar, since they are almost all positive by
immunohistochemistry for nuclear β-catenin. Taking into
consideration that nevi are thought (based on histology of
patient tumors) to be precursors for a significant portion of
melanomas, it is not so surprising that in some systems, the
presenceofactive Wnt/β-cateninsignalingmaybeneededfor
melanoma development. The dysregulation of Wnt/β-catenin
homeostasis is reflected in the observation that nuclear β-
catenin decreases with melanoma progression. Further studies
will be needed to determine whether this loss of signaling
represents a cause or effect of melanoma-genesis.
Unlike colon cancer, where mutation or loss of APC plays
a primary role in constitutive activation of the pathway,
studies have found that mutations leading to constitutive
Wnt/β-catenin signaling in melanoma are rare. As a result, it
is thought that the activation of Wnt/β-catenin signaling in
benign nevi and melanomas is likely driven by Wnt ligand,
either secreted by tumor cells themselves or from cells in the
surrounding environment. Based on studies in cell-based
systems, the signaling induced by secreted Wnt ligand is
more susceptible to regulation than constitutive activation of
the pathway by downstream mutations, suggesting that from
a therapeutic point of view, the cause of activated Wnt/β-
catenin signaling in different cancer contexts is an essential
consideration. Additionally, in cases like melanoma where
Wnt/β-catenin homeostasis is largely mediated by Wnt
ligand, the role of this pathway in cancer progression may
be more difficult to dissect since it likely involves complex
interactions between Wnt/β-catenin signaling and other




is subject to regulation by cellular, temporal, and spatial
contexts that make it difficult to generalize the end results of
pathway activation or inhibition. To this end, it is overly
simplistic to think of the pathway as oncogenic or tumor-
suppressive. While it is easy to draw conclusions from
experiments in cell culture dishes or in mouse models, these
findingsshouldbereconciledparticularlywithdataonWnt/β-
catenin activation in human tumors.
In studying the role of Wnt/β-catenin signaling in
melanoma, we need to address two critical questions. First,
howwelldothemousemodelsofmelanomarecapitulatewhat
is seen in patient tumors with regard to the loss of Wnt/β-
catenin signaling during tumor progression? Second, how
reliable is our evaluation of Wnt/β-catenin activation in
patient tumors using nuclear β-catenin as our sole measure-
ment? The context-specific nature of Wnt/β-catenin signaling
may preclude the development of universally applicable
assaysbasedongenetargets,but further studies couldidentify
context-specific readouts that could be used in melanoma or
other diseases to validate the presence or absence of nuclear
β-cateninandprovidearobustindicatorofpathwayactivation
in tumors. By developing reliable models and a faithful set of
cell and tissue assays for human diseases, we can begin to
fully grasp the cellular, spatial, and temporal contexts that
determine the consequences of Wnt/β-catenin homeostasis
and its dysregulation during disease.
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